FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug
FDA称其在早期已就康西普治疗公司被否的库欣综合征药物存在的问题作出说明

An FDA rejection letter for Corcept Therapeutics’ potential hormonal disorder drug says the agency told the company it had serious concerns before the application was submitted.
美国食品药品监督管理局(FDA)对康西普治疗公司潜在激素紊乱药物的拒信显示，该机构在申请提交前就已向公司表达了严重关切。